Vaxart is a biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Their vaccines are designed to be administered using pills that can be stored and shipped without the need of refrigeration and eliminate the risk of needle-stick injury.
Vaxart’s underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, a premium to the last closing price. The completed offering came to a value of $40 million.
Oppenheimer & Co. acted as sole bookrunner for the offering.
Thompson Hine LLP served as outside corporate and securities counsel for Vaxart. The deal was led by New York based partner Faith Charles, who leads the firm’s Life Sciences practice and co-chairs its Public Company practice.
Charles commented:
“I’m so pleased to have played a role in this deal and in helping Vaxart with its mission to develop and bring innovative vaccines and technologies to market.”